Non-Hodgkin's B-cell lymphoma: Advances in molecular strategies targeting drug resistance

Experimental Biology and Medicine

Volumn 238, Issue 9, 2013, Pages 971-990

  Maxwell, Steve A ^a   Mousavi Fard, Seyed ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Akt; apoptosis; B cell lymphoma; cluster differentiation antigens; drug metabolism; Drug resistance; epigenetics; geranylation; MAP kinases; mechanisms of drug resistance; microRNAs; microsatellite instability; multidrug resistance; NF B; NHL; oxidative stress; p53; positive regulatory domain I protein; proteasome; retinaldehyde dehydrogenase; sphingosine kinase; stroma; stromal influences; TGF ; tyrosine kinases; zinc transporter

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BCL2 RELATED PROTEIN A1; BORTEZOMIB; CD147 ANTIGEN; CD20 ANTIGEN; GALLIUM NITRATE; GLUTATHIONE TRANSFERASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTON PUMP; REACTIVE OXYGEN METABOLITE; RETINAL DEHYDROGENASE; RITUXIMAB; SPHINGOSINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DNA DAMAGE; EPIGENETICS; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MICROSATELLITE INSTABILITY; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PERIPHERAL T CELL LYMPHOMA; PHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PRENYLATION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR SUPPRESSOR GENE; UPREGULATION;

AKT; APOPTOSIS; B-CELL LYMPHOMA; CLUSTER DIFFERENTIATION ANTIGENS; DRUG METABOLISM; DRUG RESISTANCE; EPIGENETICS; GERANYLATION; MAP KINASES; MECHANISMS OF DRUG RESISTANCE; MICRORNAS; MICROSATELLITE INSTABILITY; MULTIDRUG RESISTANCE; NFΚB; NHL; OXIDATIVE STRESS; P53; POSITIVE REGULATORY DOMAIN I PROTEIN; PROTEASOME; RETINALDEHYDE DEHYDROGENASE; SPHINGOSINE KINASE; STROMA; STROMAL INFLUENCES; TGFΒ; TYROSINE KINASES; ZINC TRANSPORTER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GENE EXPRESSION PROFILING; LYMPHOMA, B-CELL; NEOPLASM RECURRENCE, LOCAL; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84884251741     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213498985     Document Type: Article

References (398)

1. Armitage JO,Weisenburger DD.New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.J Clin Oncol. 1998;16:2780-95.
2. Coiffier B.Monoclonal antibody as therapy for malignant lymphomas.CR Biol. 2006;329:241-54.
3. Klein U,Dalla-Favera R.Germinal centres: role in B-cell physiology and malignancy.Nat Rev Immunol. 2008;8:22-33.
4. Fisher RI.CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.Important Adv Oncol. 1990;:217-25.
5. Czuczman MS,Leonard JP,Williams ME.Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.Clin Adv Hematol Oncol. 2010;8:A1-14; quiz A15.
6. Friedberg JW,Fisher RI.Diffuse large B-cell lymphoma.Hematol Oncol Clin North Am. 2008;22:941-52, ix.
7. Velasquez WS.Prognostic factors in aggressive lymphoma.J Clin Oncol. 1991;9:1320-1.
8. Velasquez WS.Prognostic factors in intermediate high grade lymphoma.Cancer Treat Res. 1993;66:37-52.
9. Fisher RI,Gaynor ER,Dahlberg S,Oken MM,Grogan TM,Mize EM,Glick JH,Coltman CA,Miller TP.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.N Engl J Med. 1993;328:1002-6.
10. Multani P,White CA,Grillo-Lopez A.Non-Hodgkin's lymphoma: review of conventional treatments.Curr Pharm Biotechnol. 2001;2:279-91.
11. Sonneveld P,de Ridder M,van der Lelie H,Nieuwenhuis K,Schouten H,Mulder A,van Reijswoud I,Hop W,Lowenberg B.Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.J Clin Oncol. 1995;13:2530-9.
12. Coffey J,Hodgson DC,Gospodarowicz MK.Therapy of non-Hodgkin's lymphoma.Eur J Nucl Med Mol Imaging. 2003;30:S28-36.
13. Swerdlow AJ.Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma.Eur J Nucl Med Mol Imaging. 2003;30:S3-12.
14. Theodossiou C,Schwarzenberger P.Non-Hodgkin's lymphomas.Clin Obstet Gynecol. 2002;45:820-9.
15. Navaratnam S,Williams GJ,Rubinger M,Pettigrew NM,Mowat MR,Begleiter A,Johnston JB.Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas.Leuk Lymph. 1998;29:139-44.
16. Wilson WH,Teruya-Feldstein J,Fest T,Harris C,Steinberg SM,Jaffe ES,Raffeld M.Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.Blood. 1997;89:601-9.
17. Holen KD,Saltz LB.New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.Lancet Oncol. 2001;2:290-7.
18. Ansell SM,Armitage J.Non-Hodgkin lymphoma: diagnosis and treatment.Mayo Clin Proc. 2005;80:1087-97.
19. O'Leary HM,Savage KJ.Novel therapies in peripheral T-cell lymphomas.Curr Hematol Malig Rep. 2008;3:213-20.
20. Cheung MC,Haynes AE,Meyer RM,Stevens A,Imrie KR.Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario.Cancer Treat Rev. 2007;33:161-76.
21. Ng AK.Diffuse large B-cell lymphoma.Semin Radiat Oncol. 2007;17:169-75.
22. Prichard M,Harris T,Williams ME,Densmore JJ.Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma.Expert Opin Pharmacother. 10:983-95.
23. Horning SJ.Natural history of and therapy for the indolent non-Hodgkin's lymphomas.Semin Oncol. 1993;20:75-88.
24. Meusers P,Hense J,Brittinger G.Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems.Leukemia. 1997;11:S60-4.
25. Schmidt C,Dreyling M.Therapy of mantle cell lymphoma: current standards and future strategies.Hematol Oncol Clin North Am. 22:953-63, ix.
26. Harris NL,Jaffe ES,Stein H,Banks PM,Chan JK,Cleary ML,Delsol G,De Wolf-Peeters C,Falini B,Gatter KC,Grogan TM,Isaacson PG,Knowles DM,Mason DY,Muller-Hermelink H,Pileri SA,Piris MA,Ralfkiaer E,Warnke RA.A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.Blood. 1994;84:1361-92.
27. Campo E,Raffeld M,Jaffe ES.Mantle-cell lymphoma.Semin Hematol. 1999;36:115-27.
28. Philip T,Guglielmi C,Hagenbeek A,Somers R,Van der Lelie H,Bron D,Sonneveld P,Gisselbrecht C,Cahn JY,Harousseau JL,Coiffier B,Biron P,Mandelli F,Chauvin F.Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.N Engl J Med. 1995;333:1540-5.
29. Niehans GA,Jaszcz W,Brunetto V,Perri RT,Gajl-Peczalska K,Wick MR,Tsuruo T,Bloomfield CD.Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas.Cancer Res. 1992;52:3768-75.
30. Bates SE,Wilson WH,Fojo AT,Alvarez M,Zhan Z,Regis J,Robey R,Hose C,Monks A,Kang YK,Chabner B.Clinical reversal of multidrug resistance.Stem Cell. 1996;14:56-63.
31. Webb M,Brun M,McNiven M,Le Couteur D,Craft P.MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders.Br J Haematol. 1998;102:710-7.
32. Houldsworth J,Petlakh M,Olshen AB,Chaganti RS.Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.Leuk Lymphoma. 2008;49:2170-80.
33. Alizadeh AA,Eisen MB,Davis RE,Ma C,Lossos IS,Rosenwald A,Boldrick JC,Sabet H,Tran T,Yu X,Powell JI,Yang L,Marti GE,Moore T,Hudson J,Lu L,Lewis DB,Tibshirani R,Sherlock G,Chan WC,Greiner TC,Weisenburger DD,Armitage JO,Warnke R,Levy R,Wilson W,Grever MR,Byrd JC,Botstein D,Brown PO,Staudt LM.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature. 2000;403:503-11.
34. Rosenwald A,Wright G,Chan WC,Connors JM,Campo E,Fisher RI,Gascoyne RD,Muller-Hermelink HK,Smeland EB,Giltnane JM,Hurt EM,Zhao H,Averett L,Yang L,Wilson WH,Jaffe ES,Simon R,Klausner RD,Powell J,Duffey PL,Longo DL,Greiner TC,Weisenburger DD,Sanger WG,Dave BJ,Lynch JC,Vose J,Armitage JO,Montserrat E,Lopez-Guillermo A,Grogan TM,Miller TP,LeBlanc M,Ott G,Kvaloy S,Delabie J,Holte H,Krajci P,Stokke T,Staudt LM.The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.N Engl J Med. 2002;346:1937-47.
35. Wright G,Tan B,Rosenwald A,Hurt EH,Wiestner A,Staudt LM.A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.Proc Natl Acad Sci USA. 2003;100:9991-6.
36. Bea S,Zettl A,Wright G,Salaverria I,Jehn P,Moreno V,Burek C,Ott G,Puig X,Yang L,Lopez-Guillermo A,Chan WC,Greiner TC,Weisenburger DD,Armitage JO,Gascoyne RD,Connors JM,Grogan TM,Braziel R,Fisher RI,Smeland EB,Kvaloy S,Holte H,Delabie J,Simon R,Powell J,Wilson WH,Jaffe ES,Montserrat E,Muller-Hermelink HK,Staudt LM,Campo E,Rosenwald A.Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.Blood. 2005;106:3183-90.
37. Davis RE,Brown KD,Siebenlist U,Staudt LM.Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.J Exp Med. 2001;194:1861-74.
38. Monti S,Savage KJ,Kutok JL,Feuerhake F,Kurtin P,Mihm M,Wu B,Pasqualucci L,Neuberg D,Aguiar RC,Cin PD,Ladd C,Pinkus GS,Salles G,Harris NL,Dalla-Faver R,Habermann TM,Aster JC,Golub TR,Shipp MA.Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.Blood. 2005;105:1851-61.
39. Leonard JP,Schattner EJ,Coleman M.Biology and management of mantle cell lymphoma.Curr Opin Oncol. 2001;13:342-7.
40. Vandenberghe E,De Wolf-Peeters C,Vaughan Hudson G,Hudson BV,Pittaluga S,Anderson L,Linch DC.The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group.Br J Haematol. 1997;99:842-7.
41. Royo C,Salaverria I,Hartmann EM,Rosenwald A,Campo E,Bea S.The complex landscape of genetic alterations in mantle cell lymphoma.Semin Cancer Biol. 2011;21:322-34.
42. Jares P,Colomer D,Campo E.Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.Nat Rev Cancer. 2007;7:750-62.
43. Smith MR.Mantle cell lymphoma: advances in biology and therapy.Curr Opin Hematol. 2008;15:415-21.
44. Martinez N,Camacho FI,Algara P,Rodriguez A,Dopazo A,Ruiz-Ballesteros E,Martin P,Martinez-Climent JA,Garcia-Conde J,Menarguez J,Solano F,Mollejo M,Piris MA.The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival.Cancer Res. 2003;63:8226-32.
45. Fu L,Lin-Lee YC,Pham LV,Tamayo A,Yoshimura L,Ford RJ.Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.Blood. 2006;107:4540-8.
46. Pham LV,Tamayo AT,Yoshimura LC,Lo P,Ford RJ.Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.J Immunol. 2003;171:88-95.
47. Shishodia S,Amin HM,Lai R,Aggarwal BB.Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.Biochem Pharmacol. 2005;70:700-13.
48. Tucker CA,Kapanen AI,Chikh G,Hoffman BG,Kyle AH,Wilson IM,Masin D,Gascoyne RD,Bally M,Klasa RJ.Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.Mol Cancer Ther. 2008;7:749-58.
49. Thieblemont C,Nasser V,Felman P,Leroy K,Gazzo S,Callet-Bauchu E,Loriod B,Granjeaud S,Gaulard P,Haioun C,Traverse-Glehen A,Baseggio L,Bertucci F,Birnbaum D,Magrangeas F,Minvielle S,Avet-Loiseau H,Salles G,Coiffier B,Berger F,Houlgatte R.Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.Blood. 2004;103:2727-37.
50. Bennaceur-Griscelli A,Bosq J,Koscielny S,Lefrere F,Turhan A,Brousse N,Hermine O,Ribrag V.High level of glutathione-S-transferase pi expression in mantle cell lymphomas.Clin Cancer Res. 2004;10:3029-34.
51. Rizzatti EG,Falcao RP,Panepucci RA,Proto-Siqueira R,Anselmo-Lima WT,Okamoto OK,Zago MA.Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways.Br J Haematol. 2005;130:516-26.
52. Rizzatti EG,Mora-Jensen H,Weniger MA,Gibellini F,Lee E,Daibata M,Lai R,Wiestner A.Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.Leuk Lymphoma. 2008;49:798-808.
53. Ghielmini M,Zucca E.How I treat mantle cell lymphoma.Blood. 2009;114:1469-76.
54. Alessi DR,James SR,Downes CP,Holmes AB,Gaffney PR,Reese CB,Cohen P.Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.Curr Biol. 1997;7:261-9.
55. Kawauchi K,Ogasawara T,Yasuyama M,Otsuka K,Yamada O.The PI3K/Akt pathway as a target in the treatment of hematologic malignancies.Anticancer Agents Med Chem. 2009;9:550-9.
56. Manning BD,Cantley LC.AKT/PKB signaling: navigating downstream.Cell. 2007;129:1261-74.
57. Stokoe D,Stephens LR,Copeland T,Gaffney PR,Reese CB,Painter GF,Holmes AB,McCormick F,Hawkins PT.Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B.Science. 1997;277:567-70.
58. Jung HJ,Chen Z,McCarty N.Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.Leuk Lymphoma. 2011;52:1066-79.
59. Baohua Y,Xiaoyan Z,Tiecheng Z,Tao Q,Daren S.Mutations of the PIK3CA gene in diffuse large B cell lymphoma.Diagn Mol Pathol. 2008;17:159-65.
60. Bonavida B.Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.Oncogene. 2007;26:3629-36.
61. Fridberg M,Servin A,Anagnostaki L,Linderoth J,Berglund M,Soderberg O,Enblad G,Rosen A,Mustelin T,Jerkeman M,Persson JL,Wingren AG.Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN.Leuk Lymphoma. 2007;48:2221-32.
62. Hasselblom S,Hansson U,Olsson M,Toren L,Bergstrom A,Nilsson-Ehle H,Andersson PO.High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Br J Haematol. 2010;149:560-8.
63. Renne C,Willenbrock K,Martin-Subero JI,Hinsch N,Doring C,Tiacci E,Klapper W,Moller P,Kuppers R,Hansmann ML,Siebert R,Brauninger A.High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma.Leukemia. 2007;21:780-7.
64. Uddin S,Bu R,Ahmed M,Hussain AR,Ajarim D,Al-Dayel F,Bavi P,Al-kuraya KS.Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.Leuk Lymphoma. 2010;51:1305-14.
65. Uddin S,Hussain AR,Ahmed M,Al-Dayel F,Bu R,Bavi P,Al-Kuraya KS.Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma.Lab Invest. 2010;90:1346-56.
66. Nakao A,Afrakhte M,Moren A,Nakayama T,Christian JL,Heuchel R,Itoh S,Kawabata M,Heldin NE,Heldin CH,ten Dijke P.Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.Nature. 1997;389:631-5.
67. Imamura T,Takase M,Nishihara A,Oeda E,Hanai J,Kawabata M,Miyazono K.Smad6 inhibits signalling by the TGF-beta superfamily.Nature. 1997;389:622-6.
68. Wendel HG,De Stanchina E,Fridman JS,Malina A,Ray S,Kogan S,Cordon-Cardo C,Pelletier J,Lowe SW.Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.Nature. 2004;428:332-7.
69. Hess G,Herbrecht R,Romaguera J,Verhoef G,Crump M,Gisselbrecht C,Laurell A,Offner F,Strahs A,Berkenblit A,Hanushevsky O,Clancy J,Hewes B,Moore L,Coiffier B.Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.J Clin Oncol. 2009;27:3822-9.
70. Shi Y,Massague J.Mechanisms of TGF-beta signaling from cell membrane to the nucleus.Cell. 2003;113:685-700.
71. Chen G,Ghosh P,Osawa H,Sasaki CY,Rezanka L,Yang J,O'Farrell TJ,Longo DL.Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines.Blood. 2007;109:5301-7.
72. Wang D,Long J,Dai F,Liang M,Feng XH,Lin X.BCL6 represses Smad signaling in transforming growth factor-beta resistance.Cancer Res. 2008;68:783-9.
73. Wendel HG,Malina A,Zhao Z,Zender L,Kogan SC,Cordon-Cardo C,Pelletier J,Lowe SW.Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.Cancer Res. 2006;66:7639-46.
74. Allard D,Figg N,Bennett MR,Littlewood TD.Akt regulates the survival of vascular smooth muscle cells via inhibition of FoxO3a and GSK3.J Biol Chem. 2008;283:19739-47.
75. Datta SR,Brunet A,Greenberg ME.Cellular survival: a play in three Akts.Genes Dev. 1999;13:2905-27.
76. del Peso L,Gonzalez-Garcia M,Page C,Herrera R,Nunez G.Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.Science. 1997;278:687-9.
77. Goldman EH,Chen L,Fu H.Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation.J Biol Chem. 2004;279:10442-9.
78. Jope RS,Johnson GV.The glamour and gloom of glycogen synthase kinase-3.Trends Biochem Sci. 2004;29:95-102.
79. Kim I,Shu CW,Xu W,Shiau CW,Grant D,Vasile S,Cosford ND,Reed JC.Chemical biology investigation of cell death pathways activated by endoplasmic reticulum stress reveals cytoprotective modulators of ASK1.J Biol Chem. 2009;284:1593-603.
80. Yan L,Lavin VA,Moser LR,Cui Q,Kanies C,Yang E.PP2A regulates the pro-apoptotic activity of FOXO1.J Biol Chem. 2008;283:7411-20.
81. Suzuki E,Umezawa K,Bonavida B.Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.Oncogene. 2007;26:6184-93.
82. Maxwell SA,Cherry EM,Bayless KJ.Akt, 14-3-3zeta, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.Leuk Lymphoma. 2011;52:849-64.
83. Maxwell SA,Li Z,Jaye D,Ballard S,Ferrell J,Fu H.14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen.J Biol Chem. 2009;284:22379-89.
84. Gupta M,Ansell SM,Novak AJ,Kumar S,Kaufmann SH,Witzig TE.Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.Blood. 2009;114:2926-35.
85. Smith SM,van Besien K,Karrison T,Dancey J,McLaughlin P,Younes A,Smith S,Stiff P,Lester E,Modi S,Doyle LA,Vokes EE,Pro B.Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.J Clin Oncol. 2010;28:4740-6.
86. Witzig TE,Reeder CB,LaPlant BR,Gupta M,Johnston PB,Micallef IN,Porrata LF,Ansell SM,Colgan JP,Jacobsen ED,Ghobrial IM,Habermann TM.A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.Leukemia. 2011;25:341-7.
87. Schatz JH.Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.Curr Oncol Rep. 2011;13:398-406.
88. Krammer PH.CD95's deadly mission in the immune system.Nature. 2000;407:789-95.
89. Plumas J,Jacob MC,Chaperot L,Molens JP,Sotto JJ,Bensa JC.Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis.Blood. 1998;91:2875-85.
90. Thomas RK,Kallenborn A,Wickenhauser C,Schultze JL,Draube A,Vockerodt M,Re D,Diehl V,Wolf J.Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells.Am J Pathol. 2002;160:1521-8.
91. Kelley RF,Totpal K,Lindstrom SH,Mathieu M,Billeci K,Deforge L,Pai R,Hymowitz SG,Ashkenazi A.Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.J Biol Chem. 2005;280:2205-12.
92. Scaffidi C,Kirchhoff S,Krammer PH,Peter ME.Apoptosis signaling in lymphocytes.Curr Opin Immunol. 1999;11:277-85.
93. Siegel RM,Chan FK,Chun HJ,Lenardo MJ.The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.Nat Immunol. 2000;1:469-74.
94. Ashkenazi A,Pai RC,Fong S,Leung S,Lawrence DA,Marsters SA,Blackie C,Chang L,McMurtrey AE,Hebert A,DeForge L,Koumenis IL,Lewis D,Harris L,Bussiere J,Koeppen H,Shahrokh Z,Schwall RH.Safety and antitumor activity of recombinant soluble Apo2 ligand.J Clin Invest. 1999;104:155-62.
95. Walczak H,Miller RE,Ariail K,Gliniak B,Griffith TS,Kubin M,Chin W,Jones J,Woodward A,Le T,Smith C,Smolak P,Goodwin RG,Rauch CT,Schuh JC,Lynch DH.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.Nat Med. 1999;5:157-63.
96. Wiley SR,Schooley K,Smolak PJ,Din WS,Huang CP,Nicholl JK,Sutherland GR,Smith TD,Rauch C,Smith CA,Goodwin RG.Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity. 1995;3:673-82.
97. Cillessen SA,Meijer CJ,Ossenkoppele GJ,Castricum KC,Westra AH,Niesten P,Muris JJ,Nijdam HF,van der Hem KG,Flens M,Hooijberg E,Oudejans JJ.Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.Br J Haematol. 2006;134:283-93.
98. Bodmer JL,Holler N,Reynard S,Vinciguerra P,Schneider P,Juo P,Blenis J,Tschopp J.TRAIL receptor-2 signals apoptosis through FADD and caspase-8.Nat Cell Biol. 2000;2:241-3.
99. Pitti RM,Marsters SA,Ruppert S,Donahue CJ,Moore A,Ashkenazi A.Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.J Biol Chem. 1996;271:12687-90.
100. Brien G,Trescol-Biemont MC,Bonnefoy-Berard N.Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.Oncogene. 2007;26:5828-32.
101. Grumont RJ,Rourke IJ,Gerondakis S.Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis.Genes Dev. 1999;13:400-11.
102. Wang CY,Guttridge DC,Mayo MW,Baldwin AS.NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis.Mol Cell Biol. 1999;19:5923-9.
103. Zong WX,Edelstein LC,Chen C,Bash J,Gelinas C.The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis.Genes Dev. 1999;13:382-7.
104. Werner AB,de Vries E,Tait SW,Bontjer I,Borst J.Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax.J Biol Chem. 2002;277:22781-8.
105. Lam LT,Davis RE,Pierce J,Hepperle M,Xu Y,Hottelet M,Nong Y,Wen D,Adams J,Dang L,Staudt LM.Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.Clin Cancer Res. 2005;11:28-40.
106. Danial NN,Korsmeyer SJ.Cell death: critical control points.Cell. 2004;116:205-19.
107. van Delft MF,Huang DC.How the Bcl-2 family of proteins interact to regulate apoptosis.Cell Res. 2006;16:203-13.
108. Puthalakath H,Strasser A.Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins.Cell Death Differ. 2002;9:505-12.
109. Sun Y,Orrenius S,Pervaiz S,Fadeel B.Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance.Blood. 2005;105:4070-7.
110. Johnstone RW,Ruefli AA,Lowe SW.Apoptosis: a link between cancer genetics and chemotherapy.Cell. 2002;108:153-64.
111. Reed JC.Bcl-2 and the regulation of programmed cell death.J Cell Biol. 1994;124:1-6.
112. Shangary S,Johnson DE.Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death.Biochemistry. 2002;41:9485-95.
113. Wang JL,Liu D,Zhang ZJ,Shan S,Han X,Srinivasula SM,Croce CM,Alnemri ES,Huang Z.Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells.Proc Natl Acad Sci USA. 2000;97:7124-9.
114. Yang J,Liu X,Bhalla K,Kim CN,Ibrado AM,Cai J,Peng TI,Jones DP,Wang X.Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.Science. 1997;275:1129-32.
115. Kluck RM,Bossy-Wetzel E,Green DR,Newmeyer DD.The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis.Science. 1997;275:1132-6.
116. Yang E,Korsmeyer SJ.Molecular thanatopsis: a discourse on the BCL2 family and cell death.Blood. 1996;88:386-401.
117. Yunis JJ,Frizzera G,Oken MM,McKenna J,Theologides A,Arnesen M.Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer.N Engl J Med. 1987;316:79-84.
118. Gascoyne RD,Adomat SA,Krajewski S,Krajewska M,Horsman DE,Tolcher AW,O'Reilly SE,Hoskins P,Coldman AJ,Reed JC,Connors JM.Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.Blood. 1997;90:244-51.
119. Hermine O,Haioun C,Lepage E,d'Agay MF,Briere J,Lavignac C,Fillet G,Salles G,Marolleau JP,Diebold J,Reyas F,Gaulard P.Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).Blood. 1996;87:265-72.
120. Hill ME,MacLennan KA,Cunningham DC,Vaughan Hudson B,Burke M,Clarke P,Di Stefano F,Anderson L,Vaughan Hudson G,Mason D,Selby P,Linch DC.Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.Blood. 1996;88:1046-51.
121. Sanchez E,Chacon I,Plaza MM,Munoz E,Cruz MA,Martinez B,Lopez L,Martinez-Montero JC,Orradre JL,Saez AI,Garcia JF,Piris MA.Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.J Clin Oncol. 1998;16:1931-9.
122. Chanan-Khan A.Bcl-2 antisense therapy in B-cell malignancies.Blood Rev. 2005;19:213-21.
123. Waters JS,Webb A,Cunningham D,Clarke PA,Raynaud F,di Stefano F,Cotter FE.Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.J Clin Oncol. 2000;18:1812-23.
124. Kitada S,Takayama S,De Riel K,Tanaka S,Reed JC.Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression.Antisense Res Dev. 1994;4:71-9.
125. Pro B,Leber B,Smith M,Fayad L,Romaguera J,Hagemeister F,Rodriguez A,McLaughlin P,Samaniego F,Zwiebel J,Lopez A,Kwak L,Younes A.Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.Br J Haematol. 2008;143:355-60.
126. Rathmell JC,Thompson CB.The central effectors of cell death in the immune system.Annu Rev Immunol. 1999;17:781-828.
127. Duckett CS,Nava VE,Gedrich RW,Clem RJ,Van Dongen JL,Gilfillan MC,Shiels H,Hardwick JM,Thompson CB.A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors.EMBO J. 1996;15:2685-94.
128. Liston P,Roy N,Tamai K,Lefebvre C,Baird S,Cherton-Horvat G,Farahani R,McLean M,Ikeda JE,MacKenzie A,Korneluk RG.Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes.Nature. 1996;379:349-53.
129. Muris JJ,Cillessen SA,Vos W,van Houdt IS,Kummer JA,van Krieken JH,Jiwa NM,Jansen PM,Kluin-Nelemans HC,Ossenkoppele GJ,Gundy C,Meijer CJ,Oudejans JJ.Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.Blood. 2005;105:2916-23.
130. Cillessen SA,Hess CJ,Hooijberg E,Castricum KC,Kortman P,Denkers F,Vos W,van de Wiel MA,Schuurhuis GJ,Ossenkoppele GJ,Meijer CJ,Oudejans JJ.Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.Clin Cancer Res. 2007;13:7012-21.
131. Cillessen SA,Reed JC,Welsh K,Pinilla C,Houghten R,Hooijberg E,Deurhof J,Castricum KC,Kortman P,Hess CJ,Ossenkoppele GJ,Meijer CJ,Oudejans JJ.Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells.Blood. 2008;111:369-75.
132. Savitsky K,Bar-Shira A,Gilad S,Rotman G,Ziv Y,Vanagaite L,Tagle DA,Smith S,Uziel T,Sfez S,Ashkenazi M,Pecker I,Frydman M,Harnik R,Patanjali SR,Simmons A,Clines GA,Sartiel A,Gatti RA,Chessa L,Sanal O,Lavin MF,Jaspers NG,Taylor AM,Arlett CF,Miki T,Weissman SM,Lovett M,Collins FS,Shiloh Y.A single ataxia telangiectasia gene with a product similar to PI-3 kinase.Science. 1995;268:1749-53.
133. Korz C,Pscherer A,Benner A,Mertens D,Schaffner C,Leupolt E,Dohner H,Stilgenbauer S,Lichter P.Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.Blood. 2002;99:4554-61.
134. Pusapati RV,Rounbehler RJ,Hong S,Powers JT,Yan M,Kiguchi K,McArthur MJ,Wong PK,Johnson DG.ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.Proc Natl Acad Sci USA. 2006;103:1446-51.
135. Shreeram S,Hee WK,Demidov ON,Kek C,Yamaguchi H,Fornace AJ,Anderson CW,Appella E,Bulavin DV.Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.J Exp Med. 2006;203:2793-9.
136. Reimann M,Loddenkemper C,Rudolph C,Schildhauer I,Teichmann B,Stein H,Schlegelberger B,Dorken B,Schmitt CA.The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo.Blood. 2007;110:2996-3004.
137. Baldwin AS.Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.J Clin Invest. 2001;107:241-6.
138. Jost PJ,Ruland J.Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.Blood. 2007;109:2700-7.
139. Hayden MS,Ghosh S.Signaling to NF-kappaB.Genes Dev. 2004;18:2195-224.
140. Karin M.Nuclear factor-kappaB in cancer development and progression.Nature. 2006;441:431-6.
141. Kim HJ,Hawke N,Baldwin AS.NF-kappaB and IKK as therapeutic targets in cancer.Cell Death Differ. 2006;13:738-47.
142. Luo JL,Kamata H,Karin M.IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy.J Clin Invest. 2005;115:2625-32.
143. Jazirehi AR,Vega MI,Chatterjee D,Goodglick L,Bonavida B.Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.Cancer Res. 2004;64:7117-26.
144. Thomas RK,Sos ML,Zander T,Mani O,Popov A,Berenbrinker D,Smola-Hess S,Schultze JL,Wolf J.Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.Clin Cancer Res. 2005;11:8186-94.
145. Bai H,Wei J,Deng C,Yang X,Wang C,Xu R.MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.Int J Hematol. 2013;97:223-31.
146. Hayashita Y,Osada H,Tatematsu Y,Yamada H,Yanagisawa K,Tomida S,Yatabe Y,Kawahara K,Sekido Y,Takahashi T.A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation.Cancer Res. 2005;65:9628-32.
147. He L,Thomson JM,Hemann MT,Hernando-Monge E,Mu D,Goodson S,Powers S,Cordon-Cardo C,Lowe SW,Hannon GJ,Hammond SM.A microRNA polycistron as a potential human oncogene.Nature. 2005;435:828-33.
148. Ota A,Tagawa H,Karnan S,Tsuzuki S,Karpas A,Kira S,Yoshida Y,Seto M.Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma.Cancer Res. 2004;64:3087-95.
149. Rao E,Jiang C,Ji M,Huang X,Iqbal J,Lenz G,Wright G,Staudt LM,Zhao Y,McKeithan TW,Chan WC,Fu K.The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.Leukemia. 2012;26:1064-72.
150. Hayashi H,Abdollah S,Qiu Y,Cai J,Xu YY,Grinnell BW,Richardson MA,Topper JN,Gimbrone MA,Wrana JL,Falb D.The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling.Cell. 1997;89:1165-73.
151. Tome ME,Baker AF,Powis G,Payne CM,Briehl MM.Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth.Cancer Res. 2001;61:2766-73.
152. Tome ME,Briehl MM.Thymocytes selected for resistance to hydrogen peroxide show altered antioxidant enzyme profiles and resistance to dexamethasone-induced apoptosis.Cell Death Differ. 2001;8:953-61.
153. Wilkinson ST,Johnson DB,Tardif HL,Tome ME,Briehl MM.Increased cytochrome c correlates with poor survival in aggressive lymphoma.Oncol Lett. 2010;1:227-30.
154. Tome ME,Johnson DB,Rimsza LM,Roberts RA,Grogan TM,Miller TP,Oberley LW,Briehl MM.A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.Blood. 2005;106:3594-601.
155. Tome ME,Lutz NW,Briehl MM.Overexpression of catalase or Bcl-2 alters glucose and energy metabolism concomitant with dexamethasone resistance.Biochim Biophys Acta. 2004;1693:57-72.
156. Certo M,Del Gaizo Moore V,Nishino M,Wei G,Korsmeyer S,Armstrong SA,Letai A.Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.Cancer Cell. 2006;9:351-65.
157. Willis SN,Fletcher JI,Kaufmann T,van Delft MF,Chen L,Czabotar PE,Ierino H,Lee EF,Fairlie WD,Bouillet P,Strasser A,Kluck RM,Adams JM,Huang DC.Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.Science. 2007;315:856-9.
158. Tome ME,Frye JB,Coyle DL,Jacobson EL,Samulitis BK,Dvorak K,Dorr RT,Briehl MM.Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance.Experimental Ther Med. 2012;3:845-52.
159. Gatenby RA,Gillies RJ.Why do cancers have high aerobic glycolysis?.Nat Rev Cancer. 2004;4:891 9-9.
160. Raghunand N,He X,van Sluis R,Mahoney B,Baggett B,Taylor CW,Paine-Murrieta G,Roe D,Bhujwalla ZM,Gillies RJ.Enhancement of chemotherapy by manipulation of tumour pH.Br J Cancer. 1999;80:1005-11.
161. De Milito A,Fais S.Tumor acidity, chemoresistance and proton pump inhibitors.Future Oncol. 2005;1:779-86.
162. Gatenby RA,Gawlinski ET.The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models.Cancer Res. 2003;63:3847-54.
163. Sennoune SR,Luo D,Martinez-Zaguilan R.Plasmalemmal vacuolar-type H+-ATPase in cancer biology.Cell Biochem Biophys. 2004;40:185-206.
164. De Milito A,Iessi E,Logozzi M,Lozupone F,Spada M,Marino ML,Federici C,Perdicchio M,Matarrese P,Lugini L,Nilsson A,Fais S.Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.Cancer Res. 2007;67:5408-17.
165. O'Brien ML,Tew KD.Glutathione and related enzymes in multidrug resistance.Eur J Cancer A. 1996;32:967-78.
166. Cowan KH,Batist G,Tulpule A,Sinha BK,Myers CE.Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats.Proc Natl Acad Sci USA. 1986;83:9328-32.
167. McGown AT,Fox BW.A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro.Cancer Chemother Pharmacol. 1986;17:223-6.
168. Robson CN,Lewis AD,Wolf CR,Hayes JD,Hall A,Proctor SJ,Harris AL,Hickson ID.Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity.Cancer Res. 1987;47:6022-7.
169. Schisselbauer JC,Silber R,Papadopoulos E,Abrams K,LaCreta FP,Tew KD.Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients.Cancer Res. 1990;50:3562-8.
170. Teicher BA,Holden SA,Kelley MJ,Shea TC,Cucchi CA,Rosowsky A,Henner WD,Frei E.III. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).Cancer Res. 1987;47:388-93.
171. Tew KD.Glutathione-associated enzymes in anticancer drug resistance.Cancer Res. 1994;54:4313-20.
172. Coiffier B,Lepage E,Briere J,Herbrecht R,Tilly H,Bouabdallah R,Morel P,Van Den Neste E,Salles G,Gaulard P,Reyes F,Lederlin P,Gisselbrecht C.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med. 2002;346:235-42.
173. Sehn LH,Donaldson J,Chhanabhai M,Fitzgerald C,Gill K,Klasa R,MacPherson N,O'Reilly S,Spinelli JJ,Sutherland J,Wilson KS,Gascoyne RD,Connors JM.Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.J Clin Oncol. 2005;23:5027-33.
174. Coiffier B,Haioun C,Ketterer N,Engert A,Tilly H,Ma D,Johnson P,Lister A,Feuring-Buske M,Radford JA,Capdeville R,Diehl V,Reyes F.Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood. 1998;92:1927-32.
175. Hess G,Flohr T,Kolbe K,Bonn S,Schuler M,Derigs HG,Huber C.Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.Ann Hematol. 2006;85:769-79.
176. Hiddemann W,Kneba M,Dreyling M,Schmitz N,Lengfelder E,Schmits R,Reiser M,Metzner B,Harder H,Hegewisch-Becker S,Fischer T,Kropff M,Reis HE,Freund M,Wormann B,Fuchs R,Planker M,Schimke J,Eimermacher H,Trumper L,Aldaoud A,Parwaresch R,Unterhalt M.Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.Blood. 2005;106:3725-32.
177. Marcus R,Imrie K,Belch A,Cunningham D,Flores E,Catalano J,Solal-Celigny P,Offner F,Walewski J,Raposo J,Jack A,Smith P.CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.Blood. 2005;105:1417-23.
178. Pfreundschuh M,Trumper L,Osterborg A,Pettengell R,Trneny M,Imrie K,Ma D,Gill D,Walewski J,Zinzani PL,Stahel R,Kvaloy S,Shpilberg O,Jaeger U,Hansen M,Lehtinen T,Lopez-Guillermo A,Corrado C,Scheliga A,Milpied N,Mendila M,Rashford M,Kuhnt E,Loeffler M.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.Lancet Oncol. 2006;7:379-91.
179. Vellenga E,van Putten WL,van't Veer MB,Zijlstra JM,Fibbe WE,van Oers MH,Verdonck LF,Wijermans PW,van Imhoff GW,Lugtenburg PJ,Huijgens PC.Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.Blood. 2008;111:537-43.
180. Maloney DG,Liles TM,Czerwinski DK,Waldichuk C,Rosenberg J,Grillo-Lopez A,Levy R.Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457-66.
181. Press OW,Appelbaum F,Ledbetter JA,Martin PJ,Zarling J,Kidd P,Thomas ED.Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.Blood. 1987;69:584-91.
182. Einfeld DA,Brown JP,Valentine MA,Clark EA,Ledbetter JA.Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.EMBO J. 1988;7:711-17.
183. Kimby E.Tolerability and safety of rituximab (MabThera).Cancer Treat Rev. 2005;31:456-73.
184. Smith MR.Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.Oncogene. 2003;22:7359-68.
185. Martin P,Furman RR,Coleman M,Leonard JP.Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.Clin Cancer Res. 2007;13:5636s-42s.
186. Coiffier B.Rituximab therapy in malignant lymphoma.Oncogene. 2007;26:3603-13.
187. Colombat P,Salles G,Brousse N,Eftekhari P,Soubeyran P,Delwail V,Deconinck E,Haioun C,Foussard C,Sebban C,Stamatoullas A,Milpied N,Boue F,Taillan B,Lederlin P,Najman A,Thieblemont C,Montestruc F,Mathieu-Boue A,Benzohra A,Solal-Celigny P.Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.Blood. 2001;97:101-6.
188. Ghielmini M,Schmitz SF,Cogliatti SB,Pichert G,Hummerjohann J,Waltzer U,Fey MF,Betticher DC,Martinelli G,Peccatori F,Hess U,Zucca E,Stupp R,Kovacsovics T,Helg C,Lohri A,Bargetzi M,Vorobiof D,Cerny T.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.Blood. 2004;103:4416-23.
189. Hainsworth JD,Litchy S,Burris HAIII,Scullin DC,Corso SW,Yardley DA,Morrissey L,Greco FA.Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.J Clin Oncol. 2002;20:4261-7.
190. Hainsworth JD,Litchy S,Shaffer DW,Lackey VL,Grimaldi M,Greco FA.Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network.J Clin Oncol. 2005;23:1088-95.
191. Lemieux B,Bouafia F,Thieblemont C,Hequet O,Arnaud P,Tartas S,Traulle C,Salles G,Coiffier B.Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud.Hematol J. 2004;5:467-71.
192. McLaughlin P,Grillo-Lopez AJ,Link BK,Levy R,Czuczman MS,Williams ME,Heyman MR,Bence-Bruckler I,White CA,Cabanillas F,Jain V,Ho AD,Lister J,Wey K,Shen D,Dallaire BK.Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825-33.
193. Maloney DG.Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.J Clin Oncol. 2005;23:6421-8.
194. Clynes RA,Towers TL,Presta LG,Ravetch JV.Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.Nat Med. 2000;6:443-6.
195. Kennedy GA,Tey SK,Cobcroft R,Marlton P,Cull G,Grimmett K,Thomson D,Gill D.Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.Br J Haematol. 2002;119:412-6.
196. Daniels I,Abulayha AM,Thomson BJ,Haynes AP.Caspase-independent killing of Burkitt lymphoma cell lines by rituximab.Apoptosis. 2006;11:1013-23.
197. Hofmeister JK,Cooney D,Coggeshall KM.Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.Blood Cells Mol Dis. 2000;26:133-43.
198. Popoff IJ,Savage JA,Blake J,Johnson P,Deans JP.The association between CD20 and Src-family Tyrosine kinases requires an additional factor.Mol Immunol. 1998;35:207-14.
199. Shan D,Ledbetter JA,Press OW.Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.Blood. 1998;91:1644-52.
200. Shan D,Ledbetter JA,Press OW.Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.Cancer Immunol Immunother. 2000;48:673-83.
201. Walshe CA,Beers SA,French RR,Chan CH,Johnson PW,Packham GK,Glennie MJ,Cragg MS.Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.J Biol Chem. 2008;283:16971-84.
202. Olejniczak SH,Hernandez-Ilizaliturri FJ,Clements JL,Czuczman MS.Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.Clin Cancer Res. 2008;14:1550-60.
203. Davidson B,Konstantinovsky S,Nielsen S,Dong HP,Berner A,Vyberg M,Reich R.Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.Clin Cancer Res. 2004;10:7335-46.
204. Gabison EE,Hoang-Xuan T,Mauviel A,Menashi S.EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair.Biochimie. 2005;87:361-8.
205. Misra S,Ghatak S,Zoltan-Jones A,Toole BP.Regulation of multidrug resistance in cancer cells by hyaluronan.J Biol Chem. 2003;278:25285-8.
206. Reimers N,Zafrakas K,Assmann V,Egen C,Riethdorf L,Riethdorf S,Berger J,Ebel S,Janicke F,Sauter G,Pantel K.Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells.Clin Cancer Res. 2004;10:3422-8.
207. Zou W,Yang H,Hou X,Zhang W,Chen B,Xin X.Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells.Cancer Lett. 2007;248:211-8.
208. Zucker S,Hymowitz M,Rollo EE,Mann R,Conner CE,Cao J,Foda HD,Tompkins DC,Toole BP.Tumorigenic potential of extracellular matrix metalloproteinase inducer.Am J Pathol. 2001;158:1921-8.
209. Illemann M,Bird N,Majeed A,Sehested M,Laerum OD,Lund LR,Dano K,Nielsen BS.MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases.Mol Cancer Res. 2006;4:293-302.
210. Jia L,Wei W,Cao J,Xu H,Miao X,Zhang J.Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells.Ann Hematol. 2009;88:753-60.
211. Simon SM,Schindler M.Cell biological mechanisms of multidrug resistance in tumors.Proc Natl Acad Sci USA. 1994;91:3497-504.
212. Gottesman MM,Pastan I.Biochemistry of multidrug resistance mediated by the multidrug transporter.Annu Rev Biochem. 1993;62:385-427.
213. Kerb R,Hoffmeyer S,Brinkmann U.ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.Pharmacogenomics. 2001;2:51-64.
214. Litman T,Druley TE,Stein WD,Bates SE.From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.Cell Mol Life Sci. 2001;58:931-59.
215. Szakacs G,Paterson JK,Ludwig JA,Booth-Genthe C,Gottesman MM.Targeting multidrug resistance in cancer.Nat Rev Drug Discov. 2006;5:219-34.
216. Kang YK,Zhan Z,Regis J,Alvarez M,Robey R,Meadows B,Dickstein B,Lee JS,Otsuki T,Stetler-Stevenson M,Jaffe ES,Solomon D,Wilson WH,Fojo A,Bate SE.Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.Blood. 1995;86:1515-24.
217. Pileri SA,Sabattini E,Falini B,Tazzari PL,Gherlinzoni F,Michieli MG,Damiani D,Zucchini L,Gobbi M,Tsuruo T,Baccarani M.Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas.Histopathology. 1991;19:131-40.
218. Ohsawa M,Ikura Y,Fukushima H,Shirai N,Sugama Y,Suekane T,Hirayama M,Hino M,Ueda M.Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.Oncology. 2005;68:422-31.
219. Moscow JA,Fairchild CR,Madden MJ,Ransom DT,Wieand HS,O'Brien EE,Poplack DG,Cossman J,Myers CE,Cowan KH.Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors.Cancer Res. 1989;49:1422-8.
220. Miller TP,Grogan TM,Dalton WS,Spier CM,Scheper RJ,Salmon SE.P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.J Clin Oncol. 1991;9:17-24.
221. Wilson WH,Bates SE,Fojo A,Bryant G,Zhan Z,Regis J,Wittes RE,Jaffe ES,Steinberg SM,Herdt J.Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.J Clin Oncol. 1995;13:1995-2004.
222. Yahanda AM,Alder KM,Fisher GA,Brophy NA,Halsey J,Hardy RI,Gosland MP,Lum BL,Sikic BI.Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.J Clin Oncol. 1992;10:1624-34.
223. Rodriguez C,Commes T,Robert J,Rossi JF.Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma.Leuk Res. 1993;17:149-56.
224. Finnegan MC,Royds J,Goepel JR,Lorigan P,Hancock BW,Goyns MH.MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy.Leuk Lymphoma. 1995;18:297-302.
225. Zhan Z,Sandor VA,Gamelin E,Regis J,Dickstein B,Wilson W,Fojo AT,Bates SE.Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.Blood. 1997;89:3795-800.
226. Goldstein LJ,Galski H,Fojo A,Willingham M,Lai SL,Gazdar A,Pirker R,Green A,Crist W,Brodeur GM,Lieber M,Cossman J,Michael M,Gottesman MM,Pastan I.Expression of a multidrug resistance gene in human cancers.J Natl Cancer Inst. 1989;81:116-24.
227. Holzmayer TA,Hilsenbeck S,Von Hoff DD,Roninson IB.Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.J Natl Cancer Inst. 1992;84:1486-91.
228. Garcia MG,Alaniz LD,Russo RIC,Alvarez E,Hajos SE.PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.Leuk Res. 2009;33:288-96.
229. Kim JE,Singh RR,Cho-Vega JH,Drakos E,Davuluri Y,Khokhar FA,Fayad L,Medeiros LJ,Vega F.Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.Mod Pathol. 2009;22:1312-20.
230. Singh RR,Kunkalla K,Qu C,Schlette E,Neelapu SS,Samaniego F,Vega F.ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.Oncogene. 2011;30:4874-86.
231. Scheper RJ,Broxterman HJ,Scheffer GL,Kaaijk P,Dalton WS,van Heijningen TH,van Kalken CK,Slovak ML,de Vries EG,van der Valk P,Meijer CJLM,Pinedo HM.Ov erexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.Cancer Res. 1993;53:1475-9.
232. Scheffer GL,Wijngaard PL,Flens MJ,Izquierdo MA,Slovak ML,Pinedo HM,Meijer CJ,Clevers HC,Scheper RJ.The drug resistance-related protein LRP is the human major vault protein.Nat Med. 1995;1:578-82.
233. Kedersha NL,Rome LH.Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA.J Cell Biol. 1986;103:699-709.
234. Izquierdo MA,Shoemaker RH,Flens MJ,Scheffer GL,Wu L,Prather TR,Scheper RJ.Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.Int J Cancer. 1996;65:230-7.
235. Kitazono M,Sumizawa T,Takebayashi Y,Chen ZS,Furukawa T,Nagayama S,Tani A,Takao S,Aikou T,Akiyama S.Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.J Natl Cancer Inst. 1999;91:1647-53.
236. Filipits M,Jaeger U,Simonitsch I,Chizzali-Bonfadin C,Heinzl H,Pirker R.Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.Clin Cancer Res. 2000;6:3417-23.
237. Wolf CR,Macpherson JS,Smyth JF.Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases.Biochem Pharmacol. 35:1577-81.
238. Batist G,Tulpule A,Sinha BK,Katki AG,Myers CE,Cowan KH.Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.J Biol Chem. 1986;261:15544-9.
239. Gupta V,Singh SV,Ahmad H,Medh RD,Awasthi YC.Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan.Biochem Pharmacol. 1989;38:1993-2000.
240. Bolton MG,Colvin OM,Hilton J.Specificity of isozymes of murine hepatic glutathione S-transferase for the conjugation of glutathione with L-phenylalanine mustard.Cancer Res. 1991;51:2410-5.
241. Lewis AD,Hickson ID,Robson CN,Harris AL,Hayes JD,Griffiths SA,Manson MM,Hall AE,Moss JE,Wolf CR.Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards.Proc Natl Acad Sci USA. 1988;85:8511-5.
242. Puchalski RB,Fahl WE.Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents.Proc Natl Acad Sci USA. 1990;87:2443-7.
243. Ribrag V,Koscielny S,Carpiuc I,Cebotaru C,Vande Walle H,Talbot M,Fenaux P,Bosq J.Prognostic value of GST-pi expression in diffuse large B-cell lymphomas.Leukemia. 2003;17:972-7.
244. Katahira T,Takayama T,Miyanishi K,Hayashi T,Ikeda T,Takahashi Y,Takimoto R,Matsunaga T,Kato J,Niitsu Y.Plasma glutathione S-transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).Clin Cancer Res. 2004;10:7934-40.
245. O'Brien KA,Muscarella DE,Bloom SE.Differential induction of apoptosis and MAP kinase signaling by mitochondrial toxicants in drug-sensitive compared to drug-resistant B-lineage lymphoid cell lines.Toxicol Appl Pharmacol. 2001;174:245-56.
246. Greenland C,Touriol C,Chevillard G,Morris SW,Bai R,Duyster J,Delsol G,Allouche M.Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.Oncogene. 2001;20:7386-97.
247. Liu Q,Schwaller J,Kutok J,Cain D,Aster JC,Williams IR,Gilliland DG.Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia.EMBO J. 2000;19:1827-38.
248. Masumoto N,Nakano S,Fujishima H,Kohno K,Niho Y.v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.Int J Cancer. 1999;80:731-7.
249. Pietras RJ,Fendly BM,Chazin VR,Pegram MD,Howell SB,Slamon DJ.Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.Oncogene. 1994;9:1829-38.
250. Raitano AB,Whang YE,Sawyers CL.Signal transduction by wild-type and leukemogenic Abl proteins.Biochim Biophys Acta. 1997;1333:F201-16.
251. Sattler M,Salgia R.Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.Cytokine Growth Factor Rev. 1997;8:63-79.
252. Zou X,Calame K.Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.J Biol Chem. 1999;274:18141-4.
253. Thomas SM,Brugge JS.Cellular functions regulated by Src family kinases.Annu Rev Cell Dev Biol. 1997;13:513-609.
254. Dal Porto JM,Gauld SB,Merrell KT,Mills D,Pugh-Bernard AE,Cambier J.B cell antigen receptor signaling 101.Mol Immunol. 2004;41:599-613.
255. Monroe JG.ITAM-mediated tonic signalling through pre-BCR and BCR complexes.Nat Rev Immunol. 2006;6:283-94.
256. Hollmann CA,Tzankov A,Martinez-Marignac VL,Baker K,Grygorczyk C,Grygorczyk R,Foulkes W,Nadeau J,Dirnhofer S,Aloyz R.Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.Leuk Res. 2010;34:585-93.
257. Brave M,Goodman V,Kaminskas E,Farrell A,Timmer W,Pope S,Harapanhalli R,Saber H,Morse D,Bullock J,Men A,Noory C,Ramchandani R,Kenna L,Booth B,Gobburu J,Jiang X,Sridhara R,Justice R,Pazdur R.Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.Clin Cancer Res. 2008;14:352-9.
258. Morris SW,Naeve C,Mathew P,James PL,Kirstein MN,Cui X,Witte DP.ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK).Oncogene. 1997;14:2175-88.
259. Greenstein S,Ghias K,Krett NL,Rosen ST.Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies.Clin Cancer Res. 2002;8:1681-94.
260. Pui CH,Relling MV,Downing JR.Acute lymphoblastic leukemia.N Engl J Med. 2004;350:1535-48.
261. Gaynon PS,Carrel AL.Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia.Adv Exp Med Biol. 1999;457:593-605.
262. Kaspers GJ,Pieters R,Klumper E,De Waal FC,Veerman AJ.Glucocorticoid resistance in childhood leukemia.Leuk Lymphoma. 1994;13:187-201.
263. Schrappe M,Reiter A,Zimmermann M,Harbott J,Ludwig WD,Henze G,Gadner H,Odenwald E,Riehm H.Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster.Leukemia. 2000;14:2205-22.
264. Tissing WJ,Meijerink JP,den Boer ML,Brinkhof B,van Rossum EF,van Wering ER,Koper JW,Sonneveld P,Pieters R.Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia.Clin Cancer Res. 2005;11:6050-6.
265. Morris SW,Kirstein MN,Valentine MB,Dittmer K,Shapiro DN,Look AT,Saltman DL.Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.Science. 1995;267:316-7.
266. Cessna MH,Zhou H,Sanger WG,Perkins SL,Tripp S,Pickering D,Daines C,Coffin CM.Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases.Mod Pathol. 2002;15:931-8.
267. Gascoyne RD,Lamant L,Martin-Subero JI,Lestou VS,Harris NL,Muller-Hermelink HK,Seymour JF,Campbell LJ,Horsman DE,Auvigne I,Espinos E,Siebert R,Delsol G.ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.Blood. 2003;102:2568-73.
268. Jazii FR,Najafi Z,Malekzadeh R,Conrads TP,Ziaee AA,Abnet C,Yazdznbod M,Karkhane AA,Salekdeh GH.Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer.World J Gastroenterol. 2006;12:7104-12.
269. Soda M,Choi YL,Enomoto M,Takada S,Yamashita Y,Ishikawa S,Fujiwara S,Watanabe H,Kurashina K,Hatanaka H,Bando M,Ohno S,Ishikawa Y,Aburatani H,Niki T,Sohara Y,Sugiyama Y,Mano H.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature. 2007;448:561-6.
270. Li R,Morris SW.Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.Med Res Rev. 2008;28:372-412.
271. Gu L,Gao J,Li Q,Zhu YP,Jia CS,Fu RY,Chen Y,Liao QK,Ma Z.Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.Leukemia. 2008;22:2091-6.
272. Marzec M,Kasprzycka M,Liu X,Raghunath PN,Wlodarski P,Wasik MA.Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.Oncogene. 2007;26:813-21.
273. Vega F,Medeiros LJ,Leventaki V,Atwell C,Cho-Vega JH,Tian L,Claret FX,Rassidakis GZ.Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.Cancer Res. 2006;66:6589-97.
274. Fan S,el-Deiry WS,Bae I,Freeman J,Jondle D,Bhatia K,Fornace AJ,Magrath I,Kohn KW,O'Connor PM.p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.Cancer Res. 1994;54:5824-30.
275. Foroutan B,Ali Ruf A,Jerwood D,Anderson D.In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy.J Pharmacol Toxicol Methods. 2007;55:58-64.
276. Kerbauy FR,Colleoni GW,Saad ST,Silva MRR,Alves AC,Aguiar KC,Albuquerque DM,Kobarg J,Seixas MT,Kerbauy J.Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma.An analysis of 51 cases and review of the literature. Leuk Lymphoma. 2004;45:2071-8.
277. Drexler HG,Fombonne S,Matsuo Y,Hu ZB,Hamaguchi H,Uphoff CC.p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?.Leukemia. 2000;14:198-206.
278. Ichikawa A,Kinoshita T,Watanabe T,Kato H,Nagai H,Tsushita K,Saito H,Hotta T.Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.N Engl J Med. 1997;337:529-34.
279. Moller MB,Gerdes AM,Skjodt K,Mortensen LS,Pedersen NT.Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.Clin Cancer Res. 1999;5:1085-91.
280. Koduru PR,Raju K,Vadmal V,Menezes G,Shah S,Susin M,Kolitz J,Broome JD.Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.Blood. 1997;90:4078-91.
281. Happo L,Cragg MS,Phipson B,Haga JM,Jansen ES,Herold MJ,Dewson G,Michalak EM,Vandenberg CJ,Smyth GK,Strasser A,Cory S,Scott CL.Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.Blood. 2010;116:5256-67.
282. Adams J.The development of proteasome inhibitors as anticancer drugs.Cancer Cell. 2004;5:417-21.
283. Richardson PG,Mitsiades C,Hideshima T,Anderson KC.Proteasome inhibition in the treatment of cancer.Cell Cycle. 2005;4:290-6.
284. Orlowski RZ,Kuhn DJ.Proteasome inhibitors in cancer therapy: lessons from the first decade.Clin Cancer Res. 2008;14:1649-57.
285. Stapnes C,Doskeland AP,Hatfield K,Ersvaer E,Ryningen A,Lorens JB,Gjertsen BT,Bruserud O.The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.Br J Haematol. 2007;136:814-28.
286. Strauss SJ,Higginbottom K,Juliger S,Maharaj L,Allen P,Schenkein D,Lister TA,Joel SP.The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.Cancer Res. 2007;67:2783-90.
287. Meister S,Schubert U,Neubert K,Herrmann K,Burger R,Gramatzki M,Hahn S,Schreiber S,Wilhelm S,Herrmann M,Jack HM,Voll RE.Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.Cancer Res. 2007;67:1783-92.
288. Obeng EA,Carlson LM,Gutman DM,Harrington WJ,Lee KP,Boise LH.Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.Blood. 2006;107:4907-16.
289. McConkey DJ,Zhu K.Mechanisms of proteasome inhibitor action and resistance in cancer.Drug Resist Updat. 2008;11:164-79.
290. Fisher RI,Bernstein SH,Kahl BS,Djulbegovic B,Robertson MJ,de Vos S,Epner E,Krishnan A,Leonard JP,Lonial S,Stadtmauer EA,O'Connor OA,Shi H,Boral AL,Goy A.Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.J Clin Oncol. 2006;24:4867-74.
291. Goy A,Younes A,McLaughlin P,Pro B,Romaguera JE,Hagemeister F,Fayad L,Dang NH,Samaniego F,Wang M,Broglio K,Samuels B,Gilles F,Sarris AH,Hart S,Trehu E,Schenkein D,Cabanillas F,Rodriguez AM.Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.J Clin Oncol. 2005;23:667-75.
292. O'Connor OA,Wright J,Moskowitz C,Muzzy J,MacGregor-Cortelli B,Stubblefield M,Straus D,Portlock C,Hamlin P,Choi E,Dumetrescu O,Esseltine D,Trehu E,Adams J,Schenkein D,Zelenetz AD.Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.J Clin Oncol. 2005;23:676-84.
293. Ruckrich T,Kraus M,Gogel J,Beck A,Ovaa H,Verdoes M,Overkleeft HS,Kalbacher H,Driessen C.Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.Leukemia. 2009;23:1098-105.
294. Glas R,Bogyo M,McMaster JS,Gaczynska M,Ploegh HL.A proteolytic system that compensates for loss of proteasome function.Nature. 1998;392:618-22.
295. Princiotta MF,Schubert U,Chen W,Bennink JR,Myung J,Crews CM,Yewdell JW.Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.Proc Natl Acad Sci USA. 2001;98:513-8.
296. Turk V,Turk B,Turk D.Lysosomal cysteine proteases: facts and opportunities.EMBO J. 2001;20:4629-33.
297. Li J,Lee AS.Stress induction of GRP78/BiP and its role in cancer.Curr Mol Med. 2006;6:45-54.
298. Mozos A,Roue G,Lopez-Guillermo A,Jares P,Campo E,Colomer D,Martinez A.The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma.Am J Pathol. 2011;179:2601-10.
299. Esteller M.Epigenetics in cancer.N Engl J Med. 2008;358:1148-59.
300. Ropero S,Esteller M.The role of histone deacetylases (HDACs) in human cancer.Mol Oncol. 2007;1:19-25.
301. Yang XJ,Seto E.The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.Nat Rev Mol Cell Biol. 2008;9:206-18.
302. Kikuchi J,Wada T,Shimizu R,Izumi T,Akutsu M,Mitsunaga K,Noborio-Hatano K,Nobuyoshi M,Ozawa K,Kano Y,Furukawa Y.Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.Blood. 2010;116:406-17.
303. Maiso P,Carvajal-Vergara X,Ocio EM,Lopez-Perez R,Mateo G,Gutierrez N,Atadja P,Pandiella A,San Miguel JF.The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.Cancer Res. 2006;66:5781-9.
304. Marks PA,Richon VM,Rifkind RA.Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.J Natl Cancer Inst. 2000;92:1210-16.
305. Sakai E,Bottaro A,Alt FW.The Ig heavy chain intronic enhancer core region is necessary and sufficient to promote efficient class switch recombination.Int Immunol. 1999;11:1709-13.
306. Marks P,Rifkind RA,Richon VM,Breslow R,Miller T,Kelly WK.Histone deacetylases and cancer: causes and therapies.Nat Rev Cancer. 1:194-202.
307. Schreiber SL,Bernstein BE.Signaling network model of chromatin.Cell. 2002;111:771-8.
308. Kim MS,Kwon HJ,Lee YM,Baek JH,Jang JE,Lee SW,Moon EJ,Kim HS,Lee SK,Chung HY,Kim CW,Kim KW.Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.Nat Med. 2001;7:437-43.
309. Mitsiades CS,Mitsiades NS,McMullan CJ,Poulaki V,Shringarpure R,Hideshima T,Akiyama M,Chauhan D,Munshi N,Gu X,Bailey C,Joseph M,Libermann TA,Richon VM,Marks PA,Anderson KC.Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.Proc Natl Acad Sci USA. 2004;101:540-5.
310. Duan H,Heckman CA,Boxer LM.Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.Mol Cell Biol. 2005;25:1608-19.
311. Bhalla S,Balasubramanian S,David K,Sirisawad M,Buggy J,Mauro L,Prachand S,Miller R,Gordon LI,Evens AM.PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.Clin Cancer Res. 2009;15:3354-65.
312. Dasmahapatra G,Lembersky D,Kramer L,Fisher RI,Friedberg J,Dent P,Grant S.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.Blood. 2010;115:4478-87.
313. Shimizu R,Kikuchi J,Wada T,Ozawa K,Kano Y,Furukawa Y.HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.Leukemia. 2010;24:1760-8.
314. Aaltonen LA,Peltomaki P,Leach FS,Sistonen P,Pylkkanen L,Mecklin JP,Jarvinen H,Powell SM,Jen J,Hamilton SR,Petersen GM,Kinzler KW,Vogelstein B,Chapelle A de la.Clues to the pathogenesis of familial colorectal cancer.Science. 1993;260:812-6.
315. Fishel R,Lescoe MK,Rao MR,Copeland NG,Jenkins NA,Garber J,Kane M,Kolodner R.The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.Cell. 1993;75:1027-38.
316. Ionov Y,Peinado MA,Malkhosyan S,Shibata D,Perucho M.Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis.Nature. 1993;363:558-61.
317. Peltomaki P,Lothe RA,Aaltonen LA,Pylkkanen L,Nystrom-Lahti M,Seruca R,David L,Holm R,Ryberg D,Haugen A,Brøgger A,Børresen A,Chapelle A de la.Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.Cancer Res. 1993;53:5853-5.
318. Thibodeau SN,Bren G,Schaid D.Microsatellite instability in cancer of the proximal colon.Science. 1993;260:816-9.
319. Miyashita K,Fujii K,Yamada Y,Hattori H,Taguchi K,Yamanaka T,Yoshida MA,Okamura J,Oda S,Muta K,Nawata H,Takayanagi R,Uike N.Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy.Leuk Res. 2008;32:1183-95.
320. Eckstein N,Servan K,Hildebrandt B,Politz A,von Jonquieres G,Wolf-Kummeth S,Napierski I,Hamacher A,Kassack MU,Budczies J,Beier M,Dietel M,Royer-Pokora B,Denkert C,Royer HD.Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.Cancer Res. 2009;69:2996-3003.
321. Williams RT,den Besten W,Sherr CJ.Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.Genes Dev. 2007;21:2283-7.
322. Bajenoff M,Egen JG,Koo LY,Laugier JP,Brau F,Glaichenhaus N,Germain RN.Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes.Immunity. 2006;25:989-1001.
323. Okada T,Ngo VN,Ekland EH,Forster R,Lipp M,Littman DR,Cyster JG.Chemokine requirements for B cell entry to lymph nodes and Peyer's patches.J Exp Med. 2002;196:65-75.
324. Meads MB,Hazlehurst LA,Dalton WS.The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.Clin Cancer Res. 2008;14:2519-26.
325. Linderoth J,Eden P,Ehinger M,Valcich J,Jerkeman M,Bendahl PO,Berglund M,Enblad G,Erlanson M,Roos G,Cavallin-Stahl E.Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.Br J Haematol. 2008;141:423-32.
326. Walker A,Taylor ST,Hickman JA,Dive C.Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells.Cancer Res. 1997;57:1939-45.
327. Taylor ST,Hickman JA,Dive C.Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas.Endocr Relat Cancer. 1999;6:21-3.
328. Shu HB,Hu WH,Johnson H.TALL-1 is a novel member of the TNF family that is down-regulated by mitogens.J Leukoc Biol. 1999;65:680-3.
329. Mercurio F,DiDonato JA,Rosette C,Karin M.p105 and p98 precursor proteins play an active role in NF-kappa B-mediated signal transduction.Genes Dev. 1993;7:705-18.
330. Naumann M,Wulczyn FG,Scheidereit C.The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B.EMBO J. 1993;12:213-22.
331. Lwin T,Crespo LA,Wu A,Dessureault S,Shu HB,Moscinski LC,Sotomayor E,Dalton WS,Tao J.Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis.Leukemia. 2009;23:170-7.
332. Briones J,Timmerman JM,Hilbert DM,Levy R.BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.Exp Hematol. 2002;30:135-41.
333. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.N Engl J Med. 1993;329:987-94.
334. Dive C,Hickman JA.Drug-target interactions: only the first step in the commitment to a programmed cell death?.Br J Cancer. 1991;64:192-6.
335. Raff MC.Social controls on cell survival and cell death.Nature. 1992;356:397-400.
336. Reed JC.Double identity for proteins of the Bcl-2 family.Nature. 1997;387:773-6.
337. Taylor ST,Hickman JA,Dive C.Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.J Natl Cancer Inst. 2000;92:18-23.
338. Trikha M,Corringham R,Klein B,Rossi JF.Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.Clin Cancer Res. 2003;9:4653-65.
339. Gilbert LA,Hemann MT.DNA damage-mediated induction of a chemoresistant niche.Cell. 2010;143:355-66.
340. Trentin L,Cabrelle A,Facco M,Carollo D,Miorin M,Tosoni A,Pizzo P,Binotto G,Nicolardi L,Zambello R,Adami F,Agostini C,Semenzato G.Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas.Blood. 2004;104:502-8.
341. Burger JA,Burger M,Kipps TJ.Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.Blood. 1999;94:3658-67.
342. Burkle A,Niedermeier M,Schmitt-Graff A,Wierda WG,Keating MJ,Burger JA.Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.Blood. 2007;110:3316-25.
343. Sipkins DA,Wei X,Wu JW,Runnels JM,Cote D,Means TK,Luster AD,Scadden DT,Lin CP.In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment.Nature. 2005;:435 969-73.
344. Burger JA,Kipps TJ.Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells.Leuk Lymphoma. 2002;43:461-6.
345. Lenz G,Wright G,Dave SS,Xiao W,Powell J,Zhao H,Xu W,Tan B,Goldschmidt N,Iqbal J,Vose J,Bast M,Fu K,Weisenburger DD,Greiner TC,Armitage JO,Kyle A,May L,Gascoyne RD,Connors JM,Troen G,Holte H,Kvaloy S,Dierickx D,Verhoef G,Delabie J,Smeland EB,Jares P,Martinez A,Lopez-Guillermo A,Montserrat E,Campo E,Braziel RM,Miller TP,Rimsza LM,Cook JR,Pohlman B,Sweetenham J,Tubbs RR,Fisher RI,Hartmann E,Rosenwald A,Ott G,Muller-Hermelink HK,Wrench D,Lister TA,Jaffe ES,Wilson WH,Chan WC,Staudt LM.Stromal gene signatures in large-B-cell lymphomas.N Engl J Med. 2008;359:2313-23.
346. Allen CD,Ansel KM,Low C,Lesley R,Tamamura H,Fujii N,Cyster JG.Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5.Nat Immunol. 2004;5:943-52.
347. Reif K,Ekland EH,Ohl L,Nakano H,Lipp M,Forster R,Cyster JG.Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position.Nature. 2002;416:94-9.
348. Springer TA.Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.Cell. 1994;76:301-14.
349. Byers RJ,Sakhinia E,Joseph P,Glennie C,Hoyland JA,Menasce LP,Radford JA,Illidge T.Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.Blood. 2008;111:4764-70.
350. Dave SS,Wright G,Tan B,Rosenwald A,Gascoyne RD,Chan WC,Fisher RI,Braziel RM,Rimsza LM,Grogan TM,Miller TP,LeBlanc M,Greiner TC,Weisenburger DD,Lynch JC,Vose J,Armitage JO,Smeland EB,Kvaloy S,Holte H,Delabie J,Connors JM,Lansdorp PM,Ouyang Q,Lister TA,Davies AJ,Norton AJ,Muller-Hermelink HK,Ott G,Campo E,Montserrat E,Wilson WH,Jaffe ES,Simon R,Yang L,Powell J,Zhao H,Goldschmidt N,Chiorazzi M,Staudt LM.Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.N Engl J Med. 2004;351:2159-69.
351. Farinha P,Masoudi H,Skinnider BF,Shumansky K,Spinelli JJ,Gill K,Klasa R,Voss N,Connors JM,Gascoyne RD.Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).Blood. 2005;106:2169-74.
352. Lee CG,Das B,Lin TL,Grimes C,Zhang X,Lavezzi T,Huang L,Cole J,Yau L,Li L.A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.Br J Haematol. 2012;158:79-90.
353. Cuvillier O,Pirianov G,Kleuser B,Vanek PG,Coso OA,Gutkind S,Spiegel S.Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate.Nature. 1996;381:800-3.
354. Maceyka M,Payne SG,Milstien S,Spiegel S.Sphingosine kinase, sphingosine-1-phosphate, and apoptosis.Biochim Biophys Acta. 2002;1585:193-201.
355. Macchia M,Barontini S,Bertini S,Di Bussolo V,Fogli S,Giovannetti E,Grossi E,Minutolo F,Danesi R.Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues.J Med Chem. 2001;44:3994-4000.
356. Bayerl MG,Bruggeman RD,Conroy EJ,Hengst JA,King TS,Jimenez M,Claxton DF,Yun JK.Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions.Leuk Lymphoma. 2008;49:948-54.
357. Ageberg M,Rydstrom K,Linden O,Linderoth J,Jerkeman M,Drott K.Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.Exp Cell Res. 2011;317:1179-91.
358. Novick P,Zerial M.The diversity of Rab proteins in vesicle transport.Curr Opin Cell Biol. 1997;9:496-504.
359. Wright LP,Philips MR.Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras.J Lipid Res. 2006;47:883-91.
360. Zerial M,McBride H.Rab proteins as membrane organizers.Nat Rev Mol Cell Biol. 2001;2:107-17.
361. Chitambar CR,Zahir SA,Ritch PS,Anderson T.Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma.Am J Clin Oncol. 1997;20:173-8.
362. Keller J,Bartolucci A,Carpenter JT,Feagler J.Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial.Cancer Treat Rep. 1986;70:1221-3.
363. Straus DJ.Gallium nitrate in the treatment of lymphoma.Semin Oncol. 2003;30:25-33.
364. Warrell RP,Coonley CJ,Straus DJ,Young CW.Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion.Cancer. 1983;51:1982-7.
365. Weick JK,Stephens RL,Baker LH,Jones SE.Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study.Cancer Treat Rep. 1983;67:823-5.
366. Chitambar CR,Zivkovic Z.Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms.Cancer Res. 1987;47:3929-34.
367. Esserman L,Takahashi S,Rojas V,Warnke R,Levy R.An epitope of the transferrin receptor is exposed on the cell surface of high-grade but not low-grade human lymphomas.Blood. 1989;74:2718-29.
368. Habeshaw JA,Lister TA,Stansfeld AG,Greaves MF.Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma.Lancet. 1983;1:498-501.
369. Harris WR,Pecoraro VL.Thermodynamic binding constants for gallium transferrin.Biochemistry. 1983;22:292-9.
370. Kiratli PO,Canpinar H,Ruacan S,Kansu E.Correlation of flow cytometric parameters and transferrin receptors with gallium-67 scintigraphic images in lymphoma patients.Nucl Med Commun. 2000;21:925-31.
371. Larson SM,Rasey JS,Allen DR,Nelson NJ,Grunbaum Z,Harp GD,Williams DL.Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor.J Natl Cancer Inst. 1980;64:41-53.
372. Yang M,Kroft SH,Chitambar CR.Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate.Mol Cancer Ther. 2007;6:633-43.
373. Shapiro-Shelef M,Calame K.Regulation of plasma-cell development.Nat Rev Immunol. 2005;5:230-42.
374. Shapiro-Shelef M,Lin KI,Savitsky D,Liao J,Calame K.Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow.J Exp Med. 2005;202:1471-6.
375. Gyory I,Fejer G,Ghosh N,Seto E,Wright KL.Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines.J Immunol. 2003;170:3125-33.
376. Johnson K,Shapiro-Shelef M,Tunyaplin C,Calame K.Regulatory events in early and late B-cell differentiation.Mol Immunol. 2005;42:749-61.
377. Garcia JF,Roncador G,Sanz AI,Maestre L,Lucas E,Montes-Moreno S,Fernandez Victoria R,Martinez-Torrecuadrara JL,Marafioti T,Mason DY,Piris MA.PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.Haematologica. 2006;91:467-74.
378. Friedman HS,Colvin OM,Kaufmann SH,Ludeman SM,Bullock N,Bigner DD,Griffith OW.Cyclophosphamide resistance in medulloblastoma.Cancer Res. 1992;52:5373-8.
379. Jones RJ,Barber JP,Vala MS,Collector MI,Kaufmann SH,Ludeman SM,Colvin OM,Hilton J.Assessment of aldehyde dehydrogenase in viable cells.Blood. 1995;85:2742-6.
380. Brennan SK,Meade B,Wang Q,Merchant AA,Kowalski J,Matsui W.Mantle cell lymphoma activation enhances bortezomib sensitivity.Blood. 2010;116:4185-91.
381. Corti S,Locatelli F,Papadimitriou D,Donadoni C,Salani S,Del Bo R,Strazzer S,Bresolin N,Comi GP.Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity.Stem Cell. 2006;24:975-85.
382. Hess DA,Meyerrose TE,Wirthlin L,Craft TP,Herrbrich PE,Creer MH,Nolta JA.Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity.Blood. 2004;104:1648-55.
383. Jones RJ,Gocke CD,Kasamon YL,Miller CB,Perkins B,Barber JP,Vala MS,Gerber JM,Gellert LL,Siedner M,Lemas MV,Brennan S,Ambinder RF,Matsui W.Circulating clonotypic B cells in classic Hodgkin lymphoma.Blood. 2009;113:5920-6.
384. Matsui W,Huff CA,Wang Q,Malehorn MT,Barber J,Tanhehco Y,Smith BD,Civin CI,Jones RJ.Characterization of clonogenic multiple myeloma cells.Blood. 2004;103:2332-6.
385. Hilton J.Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.Cancer Res. 2004;44:5156-60.
386. Kastan MB,Schlaffer E,Russo JE,Colvin OM,Civin CI,Hilton J.Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.Blood. 75:1947-50.
387. Kohn FR,Sladek NE.Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.Biochem Pharmacol. 1985;34:3465-71.
388. Magni M,Shammah S,Schiro R,Mellado W,Dalla-Favera R,Gianni AM.Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer.Blood. 1996;87:1097-103.
389. Russo JE,Hilton J.Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells.Cancer Res. 1988;48:2963-8.
390. Compagno M,Lim WK,Grunn A,Nandula SV,Brahmachary M,Shen Q,Bertoni F,Ponzoni M,Scandurra M,Califano A,Bhagat G,Chadburn A,Dalla-Favera R,Pasqualucci L.Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.Nature. 2009;459:717-21.
391. Dunleavy K,Pittaluga S,Czuczman MS,Dave SS,Wright G,Grant N,Shovlin M,Jaffe ES,Janik JE,Staudt LM,Wilson WH.Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.Blood. 2009;113:6069-76.
392. Catley L,Weisberg E,Kiziltepe T,Tai YT,Hideshima T,Neri P,Tassone P,Atadja P,Chauhan D,Munshi NC,Anderson KC.Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.Blood. 2006;108:3441-9.
393. Dai Y,Chen S,Kramer LB,Funk VL,Dent P,Grant S.Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.Clin Cancer Res. 2008;14:549-58.
394. Lewis TS,McCormick RS,Emmerton K,Lau JT,Yu SF,McEarchern JA,Grewal IS,Law CL.Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.Clin Cancer Res. 2011;17:4672-81.
395. Hutter G,Rieken M,Pastore A,Weigert O,Zimmermann Y,Weinkauf M,Hiddemann W,Dreyling M.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.Ann Hematol. 2012;91:847-56.
396. Lancet JE,Duong VH,Winton EF,Stuart RK,Burton M,Zhang S,Cubitt C,Blaskovich MA,Wright JJ,Sebti S,Sullivan DM.A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.Clin Cancer Res. 2011;17:1140-6.
397. Zhao XF,Gartenhaus RB.Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma.Expert Opinion Ther Targets. 2009;13:1085-93.
398. Deng J,Carlson N,Takeyama K,Dal Cin P,Shipp M,Letai A.BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.Cancer Cell. 2007;12:171-85.